Pfizer tops estimates, raises profit guidance even as sales fall

Pfizer connected Thursday reported third-quarter net and gross that topped estimates and hiked its full-year nett guidance, arsenic outgo cuts helped to outweigh declining income for the period.

The pharmaceutical elephantine present expects its full-year adjusted nett to travel successful betwixt $3 and $3.15 per share, up from a erstwhile guidance of $2.90 to $3.10 per share. Pfizer said that reflects its "solid" show for the year, "continued assurance successful our business" and advancement with reducing costs, among different factors. 

Pfizer said it besides includes a one-time $1.35 cardinal complaint tied to its licensing statement with Chinese biotech 3SBio, which deed net by astir 20 cents per share. The institution said its 2025 guidance besides accounts for President Donald Trump's existent tariffs connected China, Canada and Mexico, but not his threatened pharmaceutical-specific tariffs.

Pfizer maintained it full-year gross guidance of $61 cardinal to $64 billion.

Here's what the institution reported for the 3rd 4th compared with what Wall Street was expecting, based connected a survey of analysts by LSEG:

• Earnings per share: 87 cents adjusted vs. 63 cents expected
• Revenue: $16.65 cardinal vs. $16.58 cardinal expected

The results travel weeks aft Pfizer became the first drugmaker to onslaught a deal with Trump to voluntarily merchantability its medications for less, arsenic his medication pushes to nexus U.S. cause prices to cheaper ones abroad.

Under the deal, Pfizer has agreed to a three-year grace play during which the company's products won't look Trump's threatened pharmaceutical-specific tariffs – arsenic agelong arsenic the drugmaker further invests successful U.S. manufacturing. The institution plans to put $70 cardinal to reshore home cause manufacturing and probe facilities.

The results besides travel arsenic Pfizer escalates a bidding war with Novo Nordisk for the obesity biotech Metsera. Pfizer connected Monday filed its 2nd suit against the 2 companies, alleging that Novo Nordisk's effort to outbid Pfizer to get Metsera is anticompetitive.